Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth

NCT02443818 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire Dijon as lead sponsor.

NCT NCT02443818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02443818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth
Lead sponsor
Centre Hospitalier Universitaire Dijon
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
November 30, 2016
Enrollment
16 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

segmental overgrowth disorders due to pik3ca